08:16 AM EDT, 05/07/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) reported a Q1 loss Wednesday of $0.74 per diluted share, widening from a loss of $0.54 a year earlier.

Analysts polled by FactSet expected a loss of $0.36.

Revenue for the quarter ended March 31 was $166.8 million, down from $172.3 million a year earlier.

Analysts surveyed by FactSet expected $194.0 million.

Shares of the biotech company were down more than 5% in recent premarket activity.